JNJ's esketamine meets depression endpoint

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) met the primary endpoint in the Phase II SYNAPSE trial to treat treatment-resistant depression. Data were published in JAMA Psychiatry.

Next May, JNJ expects to report data from a Phase III program of esketamine in the indication...